Clinical Trial Update: Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain [Phase 2]

View source ↗

Summary

Phase 2 dose-response study of VER-01 in adults with chronic nonspecific low back pain has completed and reports characterization of dose-response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonspecific Low Back Pain

Drugs mentioned

• VER-01 (VER-01)

Snippet

Sponsor: Vertanical GmbH | Conditions: Chronic Non-specific Low Back Pain | Phase 2 | Status: COMPLETED